Aravive Announces Approximately $41.5 Million Private Placement Financing
25 oct. 2022 07h30 HE
|
Aravive, Inc.
HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced...
Aravive Receives Third Development Milestone from 3D Medicines
10 oct. 2022 16h05 HE
|
Aravive, Inc.
HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
26 sept. 2022 08h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h05 HE
|
Aravive, Inc.
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
11 août 2022 07h00 HE
|
Aravive, Inc.
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data.Presented Updated...
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
05 juil. 2022 09h07 HE
|
Aravive, Inc.
HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Appoints Rudy Howard as Chief Financial Officer
03 juin 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
26 mai 2022 17h11 HE
|
Aravive, Inc.
Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a...
Aravive to Participate in H.C. Wainwright Global Investment Conference
17 mai 2022 07h00 HE
|
Aravive, Inc.
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail...
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
12 mai 2022 07h00 HE
|
Aravive, Inc.
Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCCPresented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed...